27/02/2026
LENACAPAVIR is a long-acting injectable HIV pre-exposure prophylaxis (PrEP) administered twice yearly (every 6 months). It is designed to reduce new HIV infections and improve adherence compared to daily oral PrEP.
⚠️ Key Clarification:
✅ For HIV-negative individuals only
❌ NOT a vaccine
❌ NOT a cure for HIV
❌ NOT for people already living with HIV
📅 Timeline
Jan–Feb 2026: Regulatory approval & arrival of initial doses
Early March 2026: Phase 1 implementation begins nationwide rollout in priority counties
The Standard +1
Kenya received ~21,000 starter doses to support the first phase.
💉 Dosing Schedule
Initial injection after HIV-negative confirmation
Repeat injection every 6 months
This twice-yearly schedule improves adherence compared to daily pills. 🧪
Pre-Administration Requirements
Before giving Lenacapavir:
HIV testing (must be negative)
Risk assessment
Counseling
Baseline screening (pregnancy, STI where needed)
⚠️ Safety & Side Effects
Common side effects:
Injection site pain or nodules
Mild redness/swelling
These were common but rarely caused discontinuation.
Kenyans📊 Expected Impact
Reduce new HIV infections
Improve PrEP adherence
Reduce stigma associated with daily pills
Accelerate Kenya’s goal of ending HIV as a public health threat by 2030
📣 Key Messaging for Public Awareness
You can use this for posters or talks:
Lenacapavir PrEP Facts
✔ Long-acting HIV prevention injection
✔ Only twice per year
✔ For HIV-negative people at risk
❌ Not a vaccine
❌ Not treatment for HIV
